PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.
Saved in:
| Title: | PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod. |
|---|---|
| Authors: | Huth F; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Shakeri-Nejad K; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Gardin A; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Shah B; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Pohl O; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Pezous N; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland., Faller T; Novartis Biomedical Research, Novartis Pharma AG, Basel, Switzerland. |
| Source: | Clinical and translational science [Clin Transl Sci] 2026 Jul; Vol. 19 (7), pp. e70657. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1752-8062 |
|---|---|
| DOI: | 10.1111/cts.70657 |
